Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Transplant Conditioning Regimens and Outcomes After Allogeneic Hematopoietic Cell Transplantation (HCT) In Children and Adolescents with Acute Lymphoblastic Leukemia (ALL)

James Tracey, BS, Mei-Jie Zhang, PhD, Kathleen A Sobocinski, MS, Elizabeth L. Thiel, MD, Michael J. Eckrich, MD, MPH, Marcelo C Pasquini, MD, MS, Wael Saber, MD, MS, Daniel J. Weisdorf, MD, Mary M. Horowitz, MD, MS, Mary Eapen, MBBS

Blood (2010) 116 (21): 3506.

https://doi.org/10.1182/blood.V116.21.3506.3506

Published: 2010

Journal Articles

Long-Term Survival and Late Deaths in 2-Year Survivors of Myeloablative Allogeneic Hematopoietic-Cell Transplantation for Hematologic Disorders.

John R. Wingard, MD, Navneet S. Majhail, MD, MS, Ruta Bajorunaite, PhD, Zhiwei Wang, MS, Kathleen A. Sobocinski, MS, David Jacobsohn, MD, Mohamed L Sorror, J. Douglas Rizzo, MD, MS, Brian J. Bolwell, Gérard Socié, MD

Blood (2009) 114 (22): 520.

https://doi.org/10.1182/blood.V114.22.520.520

Published: 2009

Journal Articles

Long-Term Survival and Late Relapse in 5-Year Survivors of Allogeneic Hematopoietic-Cell Transplantation (HCT) for Chronic Myeloid Leukemia (CML) in First Chronic Phase.

John M. Goldman, DM, FRCP, FRCPath, Navneet S. Majhail, MD, MS, John P. Klein, PhD, Zhiwei Wang, MS, Kathleen A. Sobocinski, MS, Mukta Arora, MD, Mary M. Horowitz, MD, MS, J. Douglas Rizzo, MD, MS

Blood (2009) 114 (22): 3321.

https://doi.org/10.1182/blood.V114.22.3321.3321

Published: 2009

Journal Articles

Outcome of Bone Marrow Transplantation for Myelofibrosis.

Karen Ballen, MD, Kathleen A. Sobocinski, MS, Mei-Jie Zhang, PhD, Mukta Arora, MD, Mary M. Horowitz, MD MS, Sergio Giralt, MD, the Chronic Leukemia Working Committee of the Center for International Blood Marrow Transplant Research

Blood (2005) 106 (11): 170.

https://doi.org/10.1182/blood.V106.11.170.170

Published: 2005

Journal Articles

Matched Pairs Analysis of IV vs. PO Busulfan as a Conditioning Agent Prior to Transplantation.

Kathleen A. Sobocinski, MS, Peter F. Thall, PhD, B. Nebiyou Bekele, PhD, John P. Klein, PhD, Shari Lennon, Mary M. Horowitz, MS, MD, Borje Andersson, MD, PhD

Blood (2004) 104 (11): 349.

https://doi.org/10.1182/blood.V104.11.349.349

Published: 2004

NARROW

Transplant Conditioning Regimens and Outcomes After Allogeneic Hematopoietic Cell Transplantation (HCT) In Children and Adolescents with Acute Lymphoblastic Leukemia (ALL)

Long-Term Survival and Late Deaths in 2-Year Survivors of Myeloablative Allogeneic Hematopoietic-Cell Transplantation for Hematologic Disorders.

Long-Term Survival and Late Relapse in 5-Year Survivors of Allogeneic Hematopoietic-Cell Transplantation (HCT) for Chronic Myeloid Leukemia (CML) in First Chronic Phase.

Outcome of Bone Marrow Transplantation for Myelofibrosis.

Matched Pairs Analysis of IV vs. PO Busulfan as a Conditioning Agent Prior to Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Transplant Conditioning Regimens and Outcomes After Allogeneic Hematopoietic Cell Transplantation (HCT) In Children and Adolescents with Acute Lymphoblastic Leukemia (ALL)

Long-Term Survival and Late Deaths in 2-Year Survivors of Myeloablative Allogeneic Hematopoietic-Cell Transplantation for Hematologic Disorders.

Long-Term Survival and Late Relapse in 5-Year Survivors of Allogeneic Hematopoietic-Cell Transplantation (HCT) for Chronic Myeloid Leukemia (CML) in First Chronic Phase.

Outcome of Bone Marrow Transplantation for Myelofibrosis.

Matched Pairs Analysis of IV vs. PO Busulfan as a Conditioning Agent Prior to Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only